These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 19572350)
1. [Prodrug activation as a crucial difference. Prasugrel - a new ADP receptor antagonist]. Alban S Pharm Unserer Zeit; 2009; 38(4):320-8. PubMed ID: 19572350 [No Abstract] [Full Text] [Related]
6. Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development. Tomasello SD; Tello-Montoliu A; Angiolillo DJ Expert Opin Investig Drugs; 2011 Jan; 20(1):119-33. PubMed ID: 21143003 [TBL] [Abstract][Full Text] [Related]
7. ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly. Oprea AD; Popescu WM J Cardiothorac Vasc Anesth; 2013 Aug; 27(4):779-95. PubMed ID: 23648080 [No Abstract] [Full Text] [Related]
11. Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. Mariani M; Mariani G; De Servi S Expert Rev Cardiovasc Ther; 2009 Jan; 7(1):17-23. PubMed ID: 19105763 [TBL] [Abstract][Full Text] [Related]
12. P2Y12 inhibitors in cardiovascular disease: focus on prasugrel. Scott DM; Norwood RM; Parra D Ann Pharmacother; 2009 Jan; 43(1):64-76. PubMed ID: 19050170 [TBL] [Abstract][Full Text] [Related]
13. Prasugrel, a third generation thienopyridine and potent platelet inhibitor. Gurbel PA; Tantry US Curr Opin Investig Drugs; 2008 Mar; 9(3):324-36. PubMed ID: 18311669 [TBL] [Abstract][Full Text] [Related]
14. Prasugrel: a critical comparison with clopidogrel. Reinhart KM; White CM; Baker WL Pharmacotherapy; 2009 Dec; 29(12):1441-51. PubMed ID: 19947804 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, drug metabolism, and safety of prasugrel and clopidogrel. Achar S Postgrad Med; 2011 Jan; 123(1):73-9. PubMed ID: 21293086 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor. Dobesh PP Pharmacotherapy; 2009 Sep; 29(9):1089-102. PubMed ID: 19698014 [TBL] [Abstract][Full Text] [Related]
17. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species. Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866 [TBL] [Abstract][Full Text] [Related]
18. Prasugrel: a new antiplatelet drug for the prevention and treatment of cardiovascular disease. Koo MH; Nawarskas JJ; Frishman WH Cardiol Rev; 2008; 16(6):314-8. PubMed ID: 18923235 [TBL] [Abstract][Full Text] [Related]
19. Prasugrel: Clinical development and therapeutic application. Guerra DR; Tcheng JE Adv Ther; 2009 Nov; 26(11):999-1011. PubMed ID: 20020231 [TBL] [Abstract][Full Text] [Related]